Factor X Inhibitor Evaluation, Plasma
Use
Detection and quantitation of inhibitor to coagulation factor X. This test is utilized in clinical settings to diagnose and monitor patients suspected of having an inhibitor that specifically targets coagulation factor X. These inhibitors can arise in patients either congenitally deficient or who develop them due to other medical conditions such as postpartum state, immunologic disorders, or during certain antibiotic therapies.
Special Instructions
Not provided.
Limitations
This test may not detect all inhibitor types such as lupus anticoagulant or nonspecific inhibitors. Occasionally, a potent lupus-like anticoagulant may cause false-positive results. Specimen handling is crucial as platelet contamination can lead to erroneous outcomes.
New York Approved
Methodology
Chromosomal / Cytogenetics (Optical Clot-Based)
Biomarkers
Factor X
Analyte
LOINC Codes
- 96457-7 - Fact X Act + Inhib Pnl PPP
- 3218-5 - Fact X Act/Nor PPP
- 69049-5 - Coagulation specialist review
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
2 mL
Container
Light-blue top (3.2% sodium citrate)
Collection Instructions
Specimen must be collected prior to factor replacement therapy. Follow Coagulation Guidelines for Specimen Handling and Processing.
Patient Preparation
Fasting for 8 hours preferred. Patient must not be receiving Coumadin (warfarin) or heparin therapy.
Storage Instructions
Freeze immediately at -20°C or, ideally, -40°C or below.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |